HomeClinical TopicsFDA approves treatment of non-small cell lung cancer

FDA approves treatment of non-small cell lung cancer

The U.S. Food and Drug Administration (FDA) has approved Xalkori (crizotinib) to treat patients with late-stage non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK) gene. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content